1. Systemic and sustained thioredoxin analogue prevents acute kidney injury and its-associated distant organ damage in renal ischemia reperfusion injury mice.
- Author
-
Nishida K, Watanabe H, Miyahisa M, Hiramoto Y, Nosaki H, Fujimura R, Maeda H, Otagiri M, and Maruyama T
- Subjects
- Acute Kidney Injury metabolism, Acute Lung Injury drug therapy, Acute Lung Injury metabolism, Animals, Anti-Inflammatory Agents pharmacology, Antioxidants metabolism, Apoptosis drug effects, Disease Models, Animal, Interleukin-6 metabolism, Kidney drug effects, Kidney metabolism, Lung drug effects, Lung metabolism, Macrophage Migration-Inhibitory Factors metabolism, Male, Mice, Mice, Inbred C57BL, Oxidation-Reduction drug effects, Oxidative Stress drug effects, Reactive Oxygen Species metabolism, Reperfusion Injury metabolism, Serum Albumin metabolism, Tumor Necrosis Factor-alpha metabolism, Acute Kidney Injury prevention & control, Delayed-Action Preparations pharmacology, Reperfusion Injury drug therapy, Thioredoxins pharmacology
- Abstract
The mortality of patients with acute kidney injury (AKI) remains high due to AKI associated-lung injury. An effective strategy for preventing both AKI and AKI-associated lung injury is urgently needed. Thioredoxin-1 (Trx) is a redox-active protein that possesses anti-oxidative, anti-apoptotic and anti-inflammatory properties including modulation of macrophage migration inhibitory factor (MIF), but its short half-life limits its clinical application. Therefore, we examined the preventive effect of a long-acting Trx, which is a fusion protein of albumin and Trx (HSA-Trx), against AKI and AKI-associated lung injury. Recombinant HSA-Trx was expressed using a Pichia expression system. AKI-induced lung injury mice were generated by bilateral renal ischemia reperfusion injury (IRI). HSA-Trx administration attenuated renal IRI and its-associated lung injury. Both renal and pulmonary oxidative stress were suppressed by HSA-Trx. Moreover, HSA-Trx inhibited elevations of plasma IL-6 and TNF-α level, and suppressed IL-6-CXCL1/2-mediated neutrophil infiltration into lung and TNF-α-mediated pulmonary apoptosis. Additionally, HSA-Trx suppressed renal IRI-induced MIF expression in kidney and lung. Administration of HSA-Trx resulted in a significant increase in the survival rate of renal IRI mice. Collectively, HSA-Trx could have therapeutic utility in preventing both AKI and AKI-associated lung injury as a consequence of its systemic and sustained multiple biological action.
- Published
- 2020
- Full Text
- View/download PDF